Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial-Reference-Cited by-同舟云学术

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

Published:2018-10-11 Issue:3 Volume:22 Page:577-586
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Touchefeu Y.^ORCID,Guimbaud R.,Louvet C.,Dahan L.,Samalin E.,Barbier E.,Le Malicot K.,Cohen R.,Gornet J. M.,Aparicio T.,Nguyen S.,Azzedine A.,Etienne P. L.,Phelip J. M.,Hammel P.,Chapelle N.,Sefrioui D.,Mineur L.,Lepage C.,Bouche O.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10120-018-0885-z.pdf

Reference22 articles.

1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27. https://doi.org/10.1001/jamaoncol.2015.0735 .

2. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7. https://doi.org/10.1200/JCO.2006.06.8429 .

3. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36–46. https://doi.org/10.1056/NEJMoa073149 .

4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21. https://doi.org/10.1016/S1470-2045(08)70035-4 .

5. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. https://doi.org/10.1016/S0140-6736(10)61121-X .

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of negative emotions on patients with advanced gastric cancer receiving systemic chemotherapy: a prospective study;Journal of Gastrointestinal Oncology;2023-04

2. The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy;Frontiers in Oncology;2022-02-01

3. Machine Learning-Based Model for the Prognosis of Postoperative Gastric Cancer;Cancer Management and Research;2022-01

4. Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature;Cancer Treatment Reviews;2021-11

5. Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors;Frontiers in Oncology;2021-04-16